Che-Kai Tsao, MD Email Che-Kai Tsao
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
- Cancer (Oncology)
- Chinese (Mandarin)
- Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
He is an Assistant Professor of Medicine, Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai and is on staff at the Tisch Cancer Institute of the Mount Sinai Hospital and the Mount Sinai Queens Infusion Center. He received his medical degree from SUNY Downstate Medical Center. He then completed a residency program in internal medicine at Long Island Jewish Medical Center of Albert Einstein College of Medicine followed by a fellowship in Hematology/Oncology at Mount Sinai. There he served as Chief Fellow and was recognized with the 2012 Mount Sinai Physician of the Year, Fellow award.
Dr. Tsao is a board certified in internal medicine, hematology, and medical oncology. He is actively involved in research on the development of novel therapies in the treatment of genitourinary cancers. He is the recipient of several Merit Awards given by the American Society of Clinical Oncology. His main focus is in defining clinical and molecular phenotype of prostate, kidney, and bladder cancers, as well as novel therapies in those disease states. He is a lead investigator in several ongoing clinical trials and has authored over 40 peer-reviewed publications.
Dr. Tsao is also a member of the American Society of Clinical Oncology, the American Association of Oncology Research, and the American Society of Hematology.
American Board of Internal Medicine
MD, SUNY Downstate Medical Center
Residency, Internal Medicine
Long Island Jewish Medical Center
Mount Sinai Hospital
Chinese (Mandarin), English, Spanish, TaiwaneseDownload the CV
GU Cancers Merit Award
American Society of Clinical Oncology
American Society of Clinical Oncology
Physician of the Year, Fellow Award
Mount Sinai Hospital
Oncology Trainee Travel Award
American Society of Clinical Oncology
Workshop on Methods in Clinical Cancer Research
Prostate Cancer, Kidney Cancer, Bladder Cancer, Testicular Cancer, and Adrenal Cancer.
Tsao CK, Galsky MD, Oh WK. Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer. European urology 2014 Jan;.
Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Dec; 30(35).
Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. Journal of the National Cancer Institute 2012 Dec; 104(23).
Tsao CK, Oh WK. Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks. Nature reviews. Clinical oncology 2012 Nov; 9(11).
Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold JH, Smith CB, Sonpavde G, Oh WK, Galsky MD. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer 2012 Jun;.
Tsao CK, Small AC, Galsky MD, Oh WK. Overcoming castration resistance in prostate cancer. Current opinion in urology 2012 May; 22(3).
Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clinical genitourinary cancer 2012 Mar; 10(1).
Tsao CK, Oh WK. Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy. Asian journal of andrology 2011 Mar; 13(2).
Liaw BC, Mehrazin R, Baker C, Sfakianos JP, Tsao CK. Management of Atypical Renal Cell Carcinomas. Current treatment options in oncology 2017 Sep; 18(10).
Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Therapeutic advances in medical oncology 2017 Apr; 9(4).
Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Oct; 35(28).
Tsao CK, Sfakianos J, Liaw B, Gimpel-Tetra K, Kemeny M, Bulone L, Shahin M, Oh WK, Galsky MD. Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. The oncologist 2016 Dec; 21(12).
Paulucci DJ, Sfakianos JP, Skanderup AJ, Kan K, Tsao CK, Galsky MD, Hakimi AA, Badani KK. Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma. Oncotarget 2017 Jan; 8(3).
Reid JA. Vaccination viewpoints. Health visitor 1989 Apr; 62(4).
Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, Casey M, Boffetta P, Oh WK, Mazumdar M, Wisnivesky JP. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Mar; 34(8).
Mehrazin R, Tsao CK, Sfakianos J, Galsky MD. Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?. Urologic oncology 2016 May; 34(5).
Galsky MD, Stensland K, Sfakianos JP, Mehrazin R, Diefenbach M, Mohamed N, Tsao CK, Boffetta P, Wiklund P, Oh WK, Mazumdar M, Ferket B. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Aug; 34(22).
Tsao CK, Galsky MD, Oh WK. Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever. European urology 2016 Nov; 70(5).
Tsao CK, Cutting E, Martin J, Oh WK. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Therapeutic advances in urology 2014 Jun; 6(3).
Galsky MD, Posner M, Holcombe RF, Lee KM, Misiukiewicz K, Tsao CK, Godbold J, Soto R, Gimpel-Tetra K, Lowe N, Oh WK. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 2014 Sep; 74(3).
Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD. Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. The oncologist 2014 Sep; 19(9).
Tsao CK, Liaw BC, Oh WK, Galsky MD. Muscle invasive bladder cancer: closing the gap between practice and evidence. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2015 Mar; 67(1).
Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J, Galsky MD, Pomerantz M, Oh WK. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. The Journal of urology 2015 Jul; 194(1).
Tsao CK, Small A, Hall S, Oh WK, Galsky MD, Buckstein M, Stock R, Ali G, Morris GJ. T2 muscle-invasive bladder cancer. Seminars in oncology 2014 Apr; 41(2).
Wang L, Gong Y, Chippada-Venkata U, Heck MM, Retz M, Nawroth R, Galsky M, Tsao CK, Schadt E, de Bono J, Olmos D, Zhu J, Oh WK. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC medicine 2015 Aug; 13.
Galsky MD, Hahn NM, Wong B, Lee KM, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao CK, Oh WK. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer chemotherapy and pharmacology 2015 Dec; 76(6).
Tsao CK, Gartrell BA, Oh WK, Galsky MD. Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert review of anticancer therapy 2012 Dec; 12(12).
Tsao CK, Liaw B, Yee T, Galsky MD, Oh WK. Metabolic and toxicological considerations of newly approved prostate cancer drugs. Expert opinion on drug metabolism & toxicology 2013 Jul; 9(7).
Goyal J, Pond GR, Galsky MD, Hendricks R, Small A, Tsao CK, Sonpavde G. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urologic oncology 2014 Jan; 32(1).
Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU international 2012 Dec; 110(11).
Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (London, England) 2012 Nov; 380(9854).
Tsao CK, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World journal of urology 2013 Dec; 31(6).
Tsao CK, Seng S, Oh WK, Galsky MD. Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Clinical Medicine Insights. Oncology 2011; 5.
Gartrell BA, Tsao CK, Galsky MD. The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies. Urologic oncology 2013 Nov; 31(8).
Galsky MD, Small AC, Tsao CK, Oh WK. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. CA: a cancer journal for clinicians; 62(5).
Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, Polkinghorne KR, Shankar A, Smith DH, Tonelli M, Warnock DG, Wen CP, Coresh J, Gansevoort RT, Hemmelgarn BR, Levey AS. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012 May; 307(18).
Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold J, Sonpavde G, Palese MA, Hall SJ, Oh WK, Galsky MD. Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World journal of urology 2013 Oct; 31(5).
Tsao CK, Small AC, Moshier EL, Gartrell BA, Wisnivesky JP, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. Trends in the use of cytoreductive nephrectomy in the United States. Clinical genitourinary cancer 2012 Sep; 10(3).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Tsao during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Pfizer Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.